>ART-123 uniquely targets both coagulation and systemic inflammatory pathways...Is that true?<
It’s true if you take out the word uniquely. If you leave uniquely in, then it’s a line-drawing game.
>Atryn's anti-inflammatory properties are not in that category?<
The MoA of ART-123/thrombomodulin is similar to that of antithrombin because the molecule is a fragment of antithrombin. However, I think it’s reasonable to expect that ART-123 will have a more difficult U.S. regulatory path than ATryn because ART-123 is not structurally close enough to plasma antithrombin for the FDA to presume that it will work the same way.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.